Does Arimidex prevent metastasis?
Answers from top 10 papers
More filters
| Papers (10) | Insight |
|---|---|
| Therefore, early therapeutic inhibition of OSM in patients with breast cancer may prevent breast cancer metastasis. | |
99 Citations | Thus, Ad-mda7 should be considered a therapeutic agent that can inhibit primary tumor growth and prevent metastasis. |
| Our results identify a novel link between GPCRs and PI3Kβ in mediating metastasis, suggesting that disruption of this link might offer a novel therapeutic target to prevent the development of metastatic disease. | |
5 Citations | Arimidex may effectively inhibit the growth of breast tumors in in vitro system by inhibiting aromatase and block estrogen dependent tumor growth. |
| Implications: This study provides a mechanistic basis for potential therapeutic interventions to prevent metastasis. | |
Open access•Journal Article 29 Citations | Early-phase treatment may provide therapeutic values to prevent MDSC-mediated lung metastasis formation in tumor-bearing hosts. |
116 Citations | Blocking the CXCR6/AKT/mTOR signaling pathway may prove beneficial to prevent metastasis and provide a more effective therapeutic strategy for PCa. |
137 Citations | This may lead to therapeutic strategies to detect and prevent metastasis at its earliest inception. |
78 Citations | Inhibiting A2B receptors may be an effective method to prevent metastasis. |
| The results presented here provide significant, new opportunities to understand and to develop treatments that prevent and possibly reverse metastasis. |
Related Questions
Are there any meroterpenoids approved by FDA for cancer treatment?5 answersMeroterpenoids have shown promising anticancer properties in various studies. While no specific meroterpenoids have been explicitly mentioned as FDA-approved for cancer treatment, research has highlighted their potential in inhibiting cancer cell growth and inducing apoptosis. Studies have identified meroterpenoids from sources like alga-derived fungi and brown seaweed, demonstrating inhibitory effects on cancer cells and potential resensitization of drug-resistant cells. These compounds have shown selectivity towards cancer cells over normal cells, inducing cell cycle arrest and apoptosis through modulation of signaling pathways. Additionally, a novel meroterpenoid compound has exhibited significant anti-tumor activity against various cancers in pharmacological experiments, suggesting its potential as an anticancer drug. Further research and clinical trials may explore the FDA approval of meroterpenoids for cancer treatment.
What are the potential effects of aminopyrimidine on cancer?4 answersAminopyrimidine compounds have shown potential effects on cancer. Zhao and Diao found that their compound inhibited the growth of cervical, prostate, colon, and breast cancer cells. Nagy et al. characterized the antiproliferative and antimetastatic properties of two aminopyrimidine hybrids on ovarian cancer cells, which resulted in cell growth inhibition and changes in cell morphology. Fu et al. designed a series of aminopyrimidine derivatives that showed inhibitory activity against EGFR mutations in lung cancer cells, with one compound demonstrating remarkable efficacy. Lee et al. developed aminophenylpyrimidines as inhibitors of AIMP2-DX2, which showed selective inhibition of lung cancer cells. These findings suggest that aminopyrimidine compounds have potential as antitumor drugs and may be worth further investigation as therapeutic candidates for various types of cancer.
Dose Darbepoetin have a role in cancer.5 answersDarbepoetin alfa, a long-acting erythropoiesis-stimulating agent (ESA), has been studied in the context of cancer treatment. It has been shown to be effective in reducing transfusion needs in patients with chemotherapy-induced anemia (CIA). In pediatric acute lymphoblastic leukemia (ALL) patients, darbepoetin alfa was found to significantly reduce the need for packed red blood cell transfusions during induction chemotherapy. In liver tumor cell lines, darbepoetin alfa was found to reduce the growth of Huh-7 cells by up-regulating the tumor-suppressor gene p53, suggesting a potential role in the treatment of solid liver tumors. In small-cell lung cancer (SCLC) patients receiving dose-dense chemotherapy, darbepoetin alfa improved quality of life and decreased the need for blood transfusions, without affecting survival or objective response rates. Overall, these findings suggest that darbepoetin alfa may have a role in the supportive care of cancer patients, particularly in reducing transfusion needs and improving quality of life.
Is it appropriate to give pain medication to metastatic cancer patient before doing ADLS?5 answersIt is appropriate to give pain medication to metastatic cancer patients before doing ADLs. Patients with advanced cancer often experience moderate to severe pain, which can cause distress for both patients and their families. Adherence to pain medication in cancer patients is crucial for successful pain therapy, and lower adherence rates are associated with lower pain relief. Patients with metastatic breast cancer tend to use their pain medications appropriately, with patients who typically experience low pain increasing their medication use in response to increases in pain. Clinicians may need to be sensitive to individual differences in factors associated with pain medication use in daily life. Therefore, providing pain medication to metastatic cancer patients before doing ADLs can help manage their pain effectively and improve their overall quality of life.
Is Arimidex an immunotherapy?6 answers
Is metastasis on Netflix?10 answers